相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment
In Hae Park et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5
Ruediger Kaspera et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes
Madhu S. Singh et al.
BREAST (2011)
A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients
Laure Elens et al.
CLINICAL CHEMISTRY (2011)
Genetic determinants of platelet response to clopidogrel
Aldona Kubica et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2011)
Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer
T. K. Bergmann et al.
PHARMACOGENOMICS JOURNAL (2011)
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
D. Wang et al.
PHARMACOGENOMICS JOURNAL (2011)
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis
Tim Bauer et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17
Alain Li-Wan-Po et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations
Rasmus S. Pedersen et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine
Giovanna Gentile et al.
JOURNAL OF HEADACHE AND PAIN (2010)
SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions
Saskia Preissner et al.
NUCLEIC ACIDS RESEARCH (2010)
New CYP2A6 gene deletion and conversion variants in a population of Black African descent
Jill C. Mwenifumbo et al.
PHARMACOGENOMICS (2010)
Pharmacogenetics and olanzapine treatment: CYP1A2☆1F and serotonergic polymorphisms influence therapeutic outcome
B. Laika et al.
PHARMACOGENOMICS JOURNAL (2010)
Polymorphisms of human cytochrome P450 2C9 and the functional relevance
Shu-Feng Zhou et al.
TOXICOLOGY (2010)
Insights into the Substrate Specificity, Inhibitors, Regulation, and Polymorphisms and the Clinical Impact of Human Cytochrome P450 1A2
Shu-Feng Zhou et al.
AAPS JOURNAL (2009)
Relation of Cytochrome P450 2C19 Loss-of-Function Polymorphism to Occurrence of Drug-Eluting Coronary Stent Thrombosis
Betti Giusti et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Substrate Specificity, Regulation, and Polymorphism of Human Cytochrome P450 2B6
Sui-Lin Mo et al.
CURRENT DRUG METABOLISM (2009)
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Shu-Feng Zhou et al.
DRUG METABOLISM REVIEWS (2009)
The role of African American ethnicity and metabolism in sentinel polychlorinated biphenyl congener serum levels
Joseph E. McGraw et al.
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY (2009)
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
Dirk Sibbing et al.
EUROPEAN HEART JOURNAL (2009)
Cytochrome P450 2C19 genetic polymorphisms in Ugandans
Jun Miura et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam
M. I. Veiga et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
Alan R. Shuldiner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine
Geetha Ramachandran et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
GENETIC POLYMORPHISM IN CYTOCHROME P450 2D6 (CYP2D6): POPULATION DISTRIBUTION OF CYP2D6 ACTIVITY
Patricia Neafsey et al.
JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS (2009)
Cytochrome P-450 Polymorphisms and Response to Clopidogrel.
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events.
Tabassome Simon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales
Johanna Sistonen et al.
PHARMACOGENETICS AND GENOMICS (2009)
Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies
Elizabeth B. Daily et al.
PHARMACOGENOMICS (2009)
Pharmacogenomics of CYP3A: considerations for HIV treatment
Sukhwinder S. Lakhman et al.
PHARMACOGENOMICS (2009)
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing
Stuart A. Scott et al.
PHARMACOGENOMICS (2009)
Global variation in CYP2C8-CYP2C9 functional haplotypes
William C. Speed et al.
PHARMACOGENOMICS JOURNAL (2009)
Comparing genetic ancestry and self-described race in African Americans born in the United States and in Africa
Rona Yaeger et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
CYP2B6: New insights into a historically overlooked cytochrome P450 isozyme
Hongbing Wang et al.
CURRENT DRUG METABOLISM (2008)
Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients
Petra Bohanec Grabar et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of black African descent
Jill C. Mwenifumbo et al.
HUMAN MUTATION (2008)
The Pharmacogenetics and Pharmacodynamics of Clopidogrel Response An Analysis From the PRINC (Plavix Response in Coronary Intervention) Trial
Patrick Gladding et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2008)
Aberrant splicing caused by single nucleotide polymorphism c.516G> T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver
Marco H. Hofmann et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents
Dietmar Trenk et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients
Dennis A. Hesselink et al.
PHARMACOGENETICS AND GENOMICS (2008)
4β-Hydroxycholesterol is a new endogenous CYP3A marker:: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians
Ulf Diczfalusy et al.
PHARMACOGENETICS AND GENOMICS (2008)
Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms
Arzu Gunes et al.
PHARMACOGENOMICS (2008)
Cytochrome P450 enzyme polymorphism frequency in indigenous and native American populations: A systematic review
Cheedy Jaja et al.
COMMUNITY GENETICS (2008)
Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism
Huijun Z. Ring et al.
PHARMACOGENETICS AND GENOMICS (2007)
Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer
S. Marsh et al.
PHARMACOGENOMICS JOURNAL (2007)
Influence of CYP2C9 genotype on warfarin dose among African-Americans and European-Americans
Nita A. Limdi et al.
PERSONALIZED MEDICINE (2007)
Genetic variability of CYP2B6 polymorphisms in four southern Chinese populations
Bing-Ying Xu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Drugs as CYP3A probes, inducers, and inhibitors
Yi-Tong Liu et al.
DRUG METABOLISM REVIEWS (2007)
Novel SNPs in cytochrome p450 oxidoreductase
Steven N. Hart et al.
DRUG METABOLISM AND PHARMACOKINETICS (2007)
Pyrosequencing™-based screening for genetic polymorphisms in cytochrome P4502B6 of potential clinical relevance
Maren Rohrbacher et al.
PHARMACOGENOMICS (2006)
Genetic polymorphisms of cytochrome P4502B6 gene in Han Chinese
Su Guan et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Intra- and inter-ethnic differences in the allele frequencies of cytochrome P4502B6 gene in Chinese
Su Guan et al.
PHARMACEUTICAL RESEARCH (2006)
CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population
Rajaa A. Mirghani et al.
PHARMACOGENETICS AND GENOMICS (2006)
Coffee, myocardial infarction, and CYP nomenclature
Magnus Ingelman-Sundberg et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents
Michael Murray
JOURNAL OF PHARMACY AND PHARMACOLOGY (2006)
Specific human CYP 450 isoform metabolism of a pentachlorobiphenyl (PCB-IUPAC# 101)
JE McGraw et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity
A Westlind-Johnsson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of paclitaxel in patients with solid tumors
M Joerger et al.
CLINICAL CANCER RESEARCH (2006)
Coffee, CYP1A2 genotype, and risk of myocardial infarction
MC Cornelis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
A common novel CTP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
SC Sim et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals
Elena Garcia-Martin et al.
MOLECULAR DIAGNOSIS & THERAPY (2006)
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel
A Henningsson et al.
CLINICAL CANCER RESEARCH (2005)
Cytochrome P450 3A polymorphisms and immunosuppressive drugs
E Thervet et al.
PHARMACOGENOMICS (2005)
Genetic variability in CYP3A5 and its possible consequences
HG Xie et al.
PHARMACOGENOMICS (2004)
Cocktail approaches and strategies in drug development: Valuable tool or flawed science?
HH Zhou et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians
KA Schoedel et al.
PHARMACOGENETICS (2004)
CYP3A variation and the evolution of salt-sensitivity variants
EE Thompson et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2004)
Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms
M Ingelman-Sundberg
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2004)
Genetic polymorphism of CYP1A2 in ethiopians affecting induction and expression: Characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1
E Aklillu et al.
MOLECULAR PHARMACOLOGY (2003)
Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour
AR Tricker
TOXICOLOGY (2003)
Inducibility of CYP1A2 by orneprazole in vivo related to the genetic polymorphism of CYP1A2
XM Han et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Summary of information on human CYP enzymes: Human P450 metabolism data
S Rendic
DRUG METABOLISM REVIEWS (2002)
Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6
M Nakajima et al.
DRUG METABOLISM REVIEWS (2002)
Molecular basis of ethnic differences in drug disposition and response
HG Xie et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2001)
分享论文
